NEEDHAM, Mass. — August 28, 2025 — Leads & Copy — Candel Therapeutics, Inc. (Candel), a biopharmaceutical company, announced that President and CEO Paul Peter Tak will participate in investor conferences and meetings in September.
Tak will participate in Citi’s 2025 Biopharma Back to School Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York, and the H.C. Wainwright 27th Annual Global Investment Conference on September 5 in New York. Live webcasts will be available on Candel’s website, with replays archived for 90 days.
Candel focuses on multimodal biological immunotherapies to fight cancer, utilizing adenovirus and herpes simplex virus gene constructs. Lead products include CAN-2409 and CAN-3110, with ongoing clinical trials.
Theodore Jenkins, Vice President, Investor Relations and Business Development, tjenkins@candeltx.com
Ben Shannon, Vice President, ICR Healthcare, CandelPR@icrhealthcare.com
Source: Candel Therapeutics, Inc.
